Duchenne muscular dystrophy (DMD) is caused by the absence of dystrophin along muscle fibers. An attractive therapeutic avenue for DMD consists in the upregulation of utrophin A, a protein with high sequence identity and functional redundancy with dystrophin. Recent work has shown that pharmacological interventions that induce a muscle fiber shift toward a slower, more oxidative phenotype with increased expression of utrophin A confer morphological and functional improvements in mdx mice. Whether such improvements result from the increased expression of utrophin A per se or are linked to other beneficial adaptations associated with the slow, oxidative phenotype remain to be established. To address this central issue, we capitalized on the use of double knockout (dKO) mice, which are mdx mice also deficient in utrophin. We first compared expression of signaling molecules and markers of the slow, oxidative phenotype in muscles of mdx versus dKO mice and found that both strains exhibit similar phenotypes. Chronic activation of 5′ adenosine monophosphate-activated protein kinase with 5-amino-4-imidazolecarboxamide riboside (AICAR) resulted in expression of a slower, more oxidative phenotype in both mdx and dKO mice. In mdx mice, this fiber type shift was accompanied by clear functional improvements that included reductions in central nucleation, IgM sarcoplasmic penetration and sarcolemmal damage resulting from eccentric contractions, as well as in increased grip strength. These important morphological and functional adaptations were not seen in AICAR-treated dKO mice. Our findings show the central role of utrophin A in mediating the functional benefits associated with expression of a slower, more oxidative phenotype in dystrophic animals.
Introduction
Duchenne muscular dystrophy (DMD) is a devastating skeletal muscle wasting disorder caused by mutations in the gene that encodes dystrophin, a large and essential cytoskeletal protein found on the cytoplasmic face of the sarcolemma (1, 2) . Dystrophin binds to filamentous actin via its N-terminus and rod domain (3, 4) , and to a group of proteins referred to as the dystrophinassociated protein complex (DAPC) via its cysteine-rich and c-terminal domains. Such molecular organization is thought to maintain the integrity of the sarcolemma during repetitive muscle contractions by forming a mechanical link between the internal cytoskeleton and extracellular matrix (5) (6) (7) . Mutations and deletions in the dystrophin gene, as seen in DMD, prevent synthesis of the full-length isoform and assembly of the DAPC, thereby making the sarcolemma extremely fragile to physical damage (8) . As a result, muscle fibers of DMD patients degenerate and the subsequent cycles of muscle degeneration and regeneration eventually fail. At that stage, the muscle mass becomes infiltrated with connective and adipose tissues (9) leading to a progressive loss of muscle function.
Despite the relative prevalence and detailed characterization of DMD, there is currently no cure or effective treatment for the disease. The main treatment routinely employed consists in the administration of glucocorticoids for symptom management. Such treatments slow the decline in muscle strength and pulmonary function, prolong the patient's ability to remain mobile and delay the onset of cardiomyopathy and scoliosis (10, 11) . However, glucocorticoids are known to have several deleterious side effects and do little more than slow down modestly the relentless progression of DMD. Accordingly, other therapeutic options are much needed and approaches including exon-skipping, stop-codon readthrough, cell therapy and viral vector-mediated gene delivery are all being intensely investigated (12) (13) (14) .
Utrophin is an autosomal homolog to dystrophin that was discovered several years ago (15) . Utrophin is also a large cytoskeletal protein that displays a high degree of sequence identity with dystrophin (16) . Despite the existence of some differences including in their roles in nNOS localization and microtubule organization (17, 18) , both utrophin and dystrophin have significant functional redundancy as several studies have indeed shown that utrophin can serve as a surrogate to dystrophin in dystrophic muscles (19) (20) (21) . However, dystrophin and utrophin have different expression patterns in mature skeletal muscle. While dystrophin is normally expressed all along the sarcolemma, utrophin is mostly confined to the myotendinous and neuromuscular junctions (22, 23) . In order for a utrophin-based therapy to be of clinical value, utrophin expression must be increased throughout dystrophic muscle fibers and extended well into extrasynaptic compartments. Ideally, such a therapeutic approach should consist in the administration of pharmacologically active compounds that activate pathways controlling utrophin expression in skeletal muscle thereby causing an upregulation in the endogenous levels of utrophin.
Several years ago, our laboratory first observed that slow, oxidative muscles express significantly more utrophin A (the skeletal muscle isoform) than their fast, glycolytic counterparts, and that this increased expression of utrophin A occurred in extrasynaptic regions of slower, more oxidative fibers (24) . This is because both the transcription of utrophin A and the stability of its mRNA are higher in slow, oxidative muscles (25) (26) (27) (28) (29) . These findings are clinically relevant because it is well established that slow, oxidative muscles are more resistant to the DMD pathology in both humans and mdx mice (14, 30) . Therefore, our work has led us (25) (26) (27) (28) (31) (32) (33) (34) to hypothesize that induction of the slow, oxidative myogenic program would greatly benefit dystrophic fibers. Over the last 10 years, our initial idea has received considerable experimental support. Indeed, various labs (35) (36) (37) (38) (39) (40) (41) (42) (43) (44) (45) including ours (25, 26, 27, 28, (31) (32) (33) (34) have shown using transgenic and pharmacological approaches that activation of signaling pathways that stimulate expression of the slow, oxidative myogenic program, which includes utrophin A upregulation, results in significant beneficial adaptations in mdx mouse muscle. However, in addition to a distinct pattern of utrophin A expression, slow, oxidative muscle fibers display many other biochemical and physiological characteristics that are clearly different than those seen in fast, glycolytic muscles including for example, sarcolemmal protein composition, oxygen transport and utilization capabilities, intracellular calcium dynamics, signaling infrastructure, proapoptotic caspase activity and resistance to oxidative stress (46) . Therefore, a central question is whether the benefits conferred onto dystrophic muscles by stimulating expression of the slow, oxidative phenotype are directly related to an increase in utrophin A expression or to some other biochemical and functional characteristics.
The objective of the current study was to define the exact role of utrophin A in the benefits associated with expression of the slow, oxidative myogenic program in dystrophic fibers. To this end, we capitalized on the availability of mdx mice in which the utrophin A gene is deleted. These mice, which are thus deficient in both dystrophin and utrophin A, are referred to as dystrophin/utrophin double knockout (dKO) mice. Moreover, our recent work (31) has shown that chronic activation of 5′ adenosine monophosphate-activated protein kinase (AMPK) with the potent pharmacological agonist 5-amino-4-imidazolecarboxamide riboside (AICAR; 47) clearly induces a slower, more oxidative phenotype in mdx mouse muscles thereby mitigating the dystrophic pathology (see also 31, 41, 48) . Here, we have thus treated both mdx and dKO mice with AICAR and determined the impact of such a pharmacological treatment on a myriad of biochemical, morphological and functional parameters. Based on our recent work (see above), we expected that increased utrophin A expression is necessary to confer functional benefits to dystrophic muscle upon pharmacological induction of the slow, oxidative phenotype.
Results
The central objective of this study was to determine the contribution of utrophin A to the benefits conferred by the slow, oxidative phenotype on dystrophic muscle fibers. To this end, we compared the improvements that are seen in mdx mice versus those that might be expected to occur in dKO mice upon induction of the slow, oxidative myogenic program achieved via chronic AICAR treatment. However, aside from their worsened pathological phenotype, muscles from dKO mice have not been characterized to the same extent as the widely used mdx mouse. Therefore, as a prerequisite to our study, we first established whether important signaling molecules were expressed at similar levels in muscles from mdx versus dKO mice. In addition to providing valuable data on the impact of utrophin deficiency in a dystrophic background, this information is key to determine whether muscles of dKO and mdx mice have the similar signaling and phenotypic capacity to respond to a chronic AICAR treatment. dKO and mdx mice express similar levels of several muscle signaling proteins
We initially investigated the content and/or activation levels of important phenotype-modifying molecules including AMPK, peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α), receptor-interacting protein 140 (RIP140) and silent information regulator two ortholog 1 (SIRT1) in the extensor digitorum longus (EDL) and soleus muscles of both dKO and mdx animals. These signaling molecules are known to control muscle plasticity and, accordingly, their expression levels in both mouse strains can clearly influence the animals' ability to express the slow, oxidative myogenic program (46) .
Since AICAR elicits the slow, oxidative myogenic program through AMPK, we measured the activation of AMPK as denoted by its phosphorylation status. AMPK phosphorylation was clearly higher (P < 0.05) in soleus versus EDL muscles in both mouse strains (Table 1 ), but no difference in the steady-state activation pattern was observed between dKO and mdx mice for both muscle types. Expression of PGC-1α, a known target of AMPK, was also higher in soleus muscles compared with EDL in both strains (P < 0.05) (Table 1) but the levels were similar between dKO and mdx mice. Similarly, the histone deacetylase SIRT1 was significantly higher in soleus compared with EDL muscles with again no difference between dKO and mdx mice (P > 0.05). Finally, RIP140 which opposes the effects of PGC-1α on the slow, oxidative myogenic program was expressed at nearly identical levels in dKO and mdx mice. In this case however, and as expected, levels were higher in the fast EDL muscles of both strains (P < 0.05) as compared with the levels seen in soleus muscles. Overall, these findings demonstrate that key muscle phenotypic-modifying molecules exhibit similar expression levels in dKO versus mdx mice thereby suggesting that muscles from both mouse strains have a similar capacity to respond to AICAR treatment. dKO and mdx mice exhibit similar muscle phenotype Several proteins have distinct expression patterns between fast, glycolytic and slow, oxidative muscles, and can thus be used as markers of muscle phenotype (49) (50) (51) (52) (53) . We further analyzed some markers of the slow, oxidative phenotype in muscles from dKO versus mdx mice because the phenotype of a muscle influences its adaptive response to pharmacological induction of a slower, more oxidative myogenic program.
As expected, expression of slow troponin and cytochrome c was significantly higher (P < 0.05) in soleus muscles of dKO and mdx mice (Table 1) . Importantly, the pattern of expression of these phenotypic markers was similar in soleus and EDL muscles from dKO versus mdx mice. The ratio of muscle fibers expressing myosin heavy chain (MHC) I and MHC II A was higher (P < 0.05) in soleus muscles compared with the EDL in both mouse strains but there were no significant differences in the levels of expression of these markers between dKO and mdx mice. Overall, it appears therefore that soleus and EDL muscles from dKO and mdx mice have similar phenotypic characteristics, indicating that AICAR treatment should induce similar adaptations in their respective muscle phenotype.
AICAR treatment alters the expression of muscle signaling proteins in dKO and mdx mice
In order to induce expression of a slower, more oxidative phenotype, we treated dKO and mdx mice for 4 weeks with the AMP analog AICAR. This drug has been previously used to elicit the slow, oxidative myogenic program in mdx mice (31, 37, 41) . Following AICAR treatment, we measured in muscles the expression and/or activation levels of the phenotypic modifiers mentioned above, partly through which AICAR triggers a conversion of the muscle toward the slower, more oxidative phenotype.
In EDL muscles, AMPK phosphorylation was not increased as a result of chronic AICAR treatment in both dKO and mdx mice (Fig. 1A ) likely due to a habituation phenomenon. In contrast, expression of one of the targets of AMPK, the transcriptional co-activator PGC-1α, was approximately 1.5-fold higher (P < 0.05) in AICAR-treated dKO and mdx mice as compared with their respective, non-treated counterparts (Fig. 1B) . Moreover, AICAR treatment caused a reduction in the expression of the transcriptional co-repressor RIP140 by at least 70% (P < 0.05) in both AICARtreated dKO and mdx mice compared with their controls (Fig. 1C) . Finally, SIRT1 expression was significantly higher (P < 0.05) in AICAR-treated versus control dKO and mdx mice (Fig. 1D ). Taken together, these results show that expression and/or activation levels of these signaling molecules were affected similarly in dKO and mdx mice by the four-week AICAR treatment.
AICAR treatment evokes a slower, more oxidative phenotype in dKO and mdx mice
To determine whether indeed the AICAR treatment successfully induced expression of a slower, more oxidative myogenic program, we analyzed markers of this phenotype in EDL muscles from dKO and mdx mice treated with AICAR or vehicle. Expression of oxidative phosphorylation (OXPHOS) complex proteins is indicative of muscle oxidative capacity (54, 55) . AICAR-treated dKO and mdx mice showed significantly higher (P < 0.05) OXPHOS complex III-core protein 2 and complex IV subunit I expression levels relative to non-treated dKO and mdx mice ( Fig. 2A and B) . Similarly, expression of cytochrome c, another important protein in the electron transport chain, was significantly increased by ∼1.7-fold (P < 0.05) in both treated dKO and mdx mice compared with their control counterparts (Fig. 2C ). There were no significant differences in the expression of these molecules between the treated dKO and mdx mice, indicating that the AICAR treatment equally increased the oxidative capacity of muscle in both strains of mice.
We also measured the expression of important contractile proteins to determine whether AICAR induced a shift toward a slower fiber type composition. Expression of the slow muscle isoform of troponin c was significantly higher (P < 0.05) in AICARtreated dKO and mdx mice compared with non-treated mice (Fig. 2D ). Immunofluorescence analyses further revealed that the ratio of MHC IIA-positive muscle fibers to the total number of fibers in EDL muscles of AICAR-treated dKO and mdx mice was ∼1.4-fold higher (P < 0.05) than the ratio seen in respective control animals (Fig. 3) . Finally, functional measurements of EDL twitch characteristics revealed a clear trend toward a slowing down of contractile kinetics following chronic AMPK activation with AICAR (Table 2) . Collectively, and in accordance with the changes seen in muscle signaling proteins described above, these results indicate that muscles of both dKO and mdx mice responded similarly to AICAR treatment, and thus exhibited a clear shift toward a slower, more oxidative phenotype.
AICAR treatment increases utrophin A and β-dystroglycan expression in mdx mouse muscle
Based on our previous work (25) (26) (27) 29, 31, 34, 56) and that of others (37,39-41,43,44,57,58), it appears that utrophin A is an important (24, 29) because its expression is under the influence of signaling proteins that also control this particular phenotype including for example, calcineurin and PGC-1α. Using western blot analysis, we found that expression of utrophin A was increased by ∼1.9-fold (P < 0.05) in the fast, glycolytic TA muscle of AICAR-treated mdx mice compared with vehicle-treated mdx animals (Fig. 4A ). This increased expression of utrophin A was also seen by immunofluorescence ( Fig. 4B and C) . As expected, dKO mice did not show any expression of utrophin A. Recent work from our laboratory (31) has shown that chronic AMPK stimulation induces reassembly of the DAPC along the sarcolemma coincident with increased utrophin A expression. We thus evaluated expression of β-dystroglycan (β-DG), a key component of the DAPC, and found that AICAR treatment of mdx mice resulted in a ∼1.5-fold increase (P < 0.05) in β-DG fluorescence intensity at the sarcolemma (Fig. 5) . No such increase was seen in muscles from AICAR-treated dKO mice.
AICAR treatment enhances sarcolemmal integrity of muscle fibers from mdx but not dKO mice
To assess the benefits that the slower, more oxidative phenotype bestowed on muscle fibers from dKO and mdx mice, we measured several markers of myofiber integrity and function. First, we quantified the degree of central nucleation in EDL muscles as an indicator of the amount of damage and regeneration. The ratio of fibers with centralized nuclei to the total number of fibers was significantly lower (P < 0.05) in wild-type mice compared with mdx and dKO mice ( Fig. 6B and C) . This ratio was significantly (P < 0.05) higher in dKO mice compared with mdx animals. AICAR treatment failed to reduce the ratio of centrally nucleated n = 6-7 for dKO and mdx mice, n = 4 for WT mice; *significant difference compared with expression in respective control mice as seen through one-way ANOVA and post-hoc tests (P < 0.05).
fibers in dKO mouse muscle, but resulted in a ∼40% reduction (P < 0.05) in central nucleation in mdx mice.
To further describe the impact of chronic AICAR treatment on the structural integrity of the sarcolemma, we performed additional immunofluorescence experiments to detect the intracellular presence of IgM on EDL cryostat sections. While normally excluded from the sarcoplasm, IgM can penetrate and accumulate within the cytoplasm of muscle fibers due to sarcolemmal damage (34, 59) . As shown in Figure 6D -F, the ratio of IgM-stained fibers to the total number of fibers in muscles from AICAR-treated mdx mice was ∼28% lower (P < 0.05) than that seen in non-treated mdx mice. On the other hand, this ratio remained unchanged in muscles from AICAR-treated dKO versus their respective controls.
AICAR improves muscle function but only in mdx mice
To further quantify the degree of improvement in AICAR-treated dystrophic mice, we performed on isolated EDL muscles, a series of repetitive eccentric contractions (EC) as we have previously done (31, 34, 56) , and monitored the extent of decline in maximal tetanic tension ex vivo (8, 34, 60) . Under these conditions, the decline in force output correlates with the amount of damage sustained by constituent muscle fibers during the repetitive contractions (8, 34, 60) . As shown in Figure 7 , and to establish a baseline, force maintenance over the 12 contractions was significantly higher (P < 0.05) in muscles from wild-type mice as compared with all other groups. On this parameter, the effects of AICAR on mdx muscles were more modest than what was seen Figure 2 . Effect of chronic AICAR treatment on muscle phenotype in EDL muscles of dKO and mdx mice. Representative western blots and quantitative analyses of the expression of (A) OXPHOS complex III-core protein 2, (B) OXPHOS complex IV subunit I, (C) cytochrome c and (D) slow troponin in wild-type (WT), control (CTL) and AICARtreated (A-T) dKO and mdx mice. n = 6-7 for dKO and mdx mice, n = 4 for WT mice; *significant difference compared with expression in respective control mice as seen through one-way ANOVA and post-hoc tests (P < 0.05). Please note that the representative western blots in panels (A) and (B) are from the same membrane, due to the use of a single cocktail antibody for the OXPHOS complexes. Accordingly, the glyceraldehyde 3-phosphate dehydrogenase (GAPDH) loading control is the same in both panels.
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with the other parameters mentioned above, but are in agreement with our recent observations (31). Nonetheless, there was a clear trend (P = 0.042-0.079) for the tetanic force to be higher in AICAR-treated mdx mice compared with their vehicle-treated mdx counterparts particularly starting after the fifth contraction (Fig. 7B) . No such trend was observed in dKO mice treated with AICAR.
During the EC protocol, muscles were bathed in 0.1% trypan blue solution, which penetrates into the cytoplasm of damaged fibers resulting from the EC. Following the 12 repetitive EC, trypan blue fluorescence intensity in non-peripheral EDL myofibers of wild-type mice was lower (P < 0.05) than that seen in all other groups of mice (Fig. 7A) . As expected, this staining intensity was the highest in muscles from dKO mice. AICAR treatment reduced the trypan blue florescence intensity in mdx mice by ∼30% (P < 0.05). However, no such benefit was observed in muscles from dKO mice.
Previous studies have shown that mdx mice have reduced forelimb muscle strength compared with wild-type mice (37, 41, 55) . Based on this, we also assessed whether AICAR treatment improves forelimb muscle strength. As depicted in Figure 7C , grip strength was significantly higher (P < 0.05) in wild-type mice compared with all other groups. AICAR-treated mdx mice displayed a significant increase in grip strength (P < 0.05) compared with vehicle-treated mdx mice. In contrast, AICAR treatment of dKO mice did not affect forelimb grip strength. Because we found significant differences in body weight between wild-type, mdx and dKO mice, we also normalized the forelimb grip strength to body weight. The data after normalization show a similar result to that observed without body weight normalization (Fig. 7D ) and, accordingly, further highlight the positive functional benefits of AICAR in mdx but not dKO mice.
Discussion
In this work, we examined the hypothesis that the beneficial adaptations of a slower, more oxidative myogenic phenotype conferred to mdx mice by chronic activation of AMPK are directly related to an induction in the expression of utrophin A. To this end, we first established that mdx and dKO mice have a similar muscle signaling capacity and phenotype. As a result, we predicted that both mouse strains would respond similarly to AICAR treatment except for functional adaptations in dKO mice due to an absence of utrophin A. Our results are coherent with our hypothesis. Indeed, both dKO and mdx mouse muscles showed increased expression of key phenotype-bending signaling molecules including PGC-1α and SIRT1 after chronic AICAR treatment. This increase in signaling promoted expression of the slower, more oxidative phenotype in dKO and mdx mice. However, only mdx mice showed increased resistance to the dystrophic process as evidenced by measuring several indicators of the muscle pathology. On the basis of these findings, we conclude that utrophin A is essential in protecting dystrophic muscle fibers following pharmacological induction of the slow, oxidative myogenic program.
As mentioned in the 'Introduction', slow, oxidative muscle fibers of DMD patients and mdx animals are known to be more resistant to the dystrophic pathology than fast, glycolytic fibers (14, 30) . An important component of the slow, oxidative program is utrophin A because its expression seems tightly regulated by signaling molecules also controlling this phenotype (25) (26) (27) 29, 31, 34, 37, (39) (40) (41) 43, 44, (56) (57) (58) . Therefore, we proposed several years ago that induction of the slow, oxidative myogenic program could provide important morphological and functional benefits to *A significant difference (P < 0.05) compared with mdx-CTL.
**Significant (P < 0.05) compared with dKO-CTL. n = 3-4.
dystrophic muscle fibers. In recent years, we (25-28,31-34) and others (35) (36) (37) (38) (39) (40) (41) (42) (43) (44) (45) have provided strong support to this idea since both transgenic or pharmacological induction of the slow, oxidative myogenic program in mdx mice offers clear protection against the dystrophic pathology. Among the various pharmacological interventions, several were shown to increase the expression of utrophin A in fast, glycolytic muscles, including AICAR, resveratrol, GW501516 and the polyphenolic constituents of green tea such as epigallocatechin gallate (61) (62) (63) . However, in addition to utrophin A levels, several components of the slow, oxidative phenotype may be envisaged to provide benefits to dystrophic muscles (32, 38, (64) (65) (66) (67) (68) . These include inherent differences between slow, oxidative versus fast, glycolytic muscles such as the sarcolemmal protein composition, oxygen transport and utilization capabilities, intracellular calcium dynamics, the contractile apparatus and the molecular signaling infrastructure (46) . In addition, the slow, oxidative myogenic program has specifically been shown to confer improved mitochondrial function, reduce mitochondrially mediated apoptosis, proapoptotic caspase activity and oxidative stress, while also improving autophagy (32, 38, (64) (65) (66) (67) (68) . By comparing the adaptive responses of muscles from mdx versus dKO mice, we examined in this study, the specific role of utrophin A in protecting dystrophic fibers following induction of the slow, oxidative myogenic program. For this, we first demonstrated that muscle from mdx and dKO mice respond similarly to AICAR treatment as evidenced by an activation of signaling molecules and a conversion of fiber type toward a slower, more oxidative one. Moreover, several morphological and functional parameters were clearly improved in mdx muscles after AICAR treatment as observed recently (31,41,48) . In Quantitative analyses of β-DG staining intensity in TA muscles of wild-type (WT), control (CTL) and AICAR-treated (A-T) dKO and mdx mice. n = 6-7 for dKO and mdx mice, n = 4 for WT mice; *significant difference compared with dKO-CTL and mdx-CTL, **significant difference compared with dKO-CTL and ***significant difference compared with mdx-CTL as seen through one-way ANOVA and post-hoc tests (P < 0.05). Arrows point to neuromuscular junctions identified via co-labeling of the tissue sections with α-bungarotoxin. Bar = 60 µm.
Human Molecular Genetics, 2015, Vol. 24, No. 5 | 1249 contrast, these morphological and functional characteristics of muscle were not improved in dKO mice after AMPK activation indicating that utrophin A is important for these beneficial adaptations to occur. The results presented here support the notion that utrophin A is key, if not entirely responsible, in mediating the beneficial adaptations linked to the induction of the slow, oxidative myofiber program in dystrophic muscle.
A recent study by Chan et al. showed that upregulation of the slow, oxidative myogenic program improved muscle strength and function in both dKO and mdx mice (69) . On the basis of this finding, it was argued that utrophin A is dispensable for these improvements to occur. In that study, the authors relied on two main experimental systems to come to this conclusion. First, they showed that transgenic overexpression of Peroxisome proliferator-activated receptor gamma coactivator 1-beta (PGC-1β) did not upregulate utrophin A or other proteins of the neuromuscular junction, but that it nonetheless induced a slower, more oxidative phenotype protective against the dystrophic pathology. Moreover, transgenic overexpression of PGC-1α, which can stimulate utrophin A expression (25, 40, 43, 70) , also caused morphological and functional adaptations in muscles from dKO mice. In both cases however, the transgenic mice overexpressed either PGC-1α or PGC-1β early during embryonic muscle development likely causing a fiber type shift prior to birth and likely affecting the normal progression of the dystrophic phenotype. Such a scenario possibly also occurred when Matsakas et al. (42) reported improvement in the muscles of mdx mice in which ERRγ was overexpressed, without an increase in utrophin A. However, such a transgenic approach is unlikely to be replicated in a clinical setting (71, 72) when boys are diagnosed in their toddler years. In fact, this latter point is partially supported by findings also presented by Chan et al. (2014) that were obtained with post-natal upregulation of PGC-1α in mice using an inducible tet-response system. With this elegant approach, Figure 6 . Effect of chronic AICAR treatment on muscle fiber damage in EDL muscles of dKO and mdx mice. Representative micrographs of myofiber central nucleation from an H&E stain in EDL muscle sections from (A) wild-type (WT), (B) control (CTL) and AICAR-treated (A-T) dKO and mdx mice; and IgM immunostaining in EDL muscle sections from (D) wild-type (WT), (E) control (CTL) and AICAR-treated (A-T) dKO and mdx mice. Quantitative analyses of the ratio of (C) fibers with central nucleation and (F) with IgM staining to the total number of myofibers in EDL muscles of wild-type (WT), control (CTL) and AICAR-treated (A-T) dKO and mdx mice. n = 6-7 for dKO and mdx mice, n = 4 for WT mice; *significant difference compared with dKO-CTL and mdx-CTL, **significant difference compared with dKO-CTL and ***significant difference compared with mdx-CTL as seen through one-way ANOVA and post-hoc tests (P < 0.05). Bar = 30 µm for (A) and 40 µm for (C). overexpression of PGC-1α was only achieved in mice after removal of doxycycline from their chow at 3 weeks of age. In such transgenic mdx mice, PGC-1α overexpression was shown to ameliorate the dystrophic phenotype. However, it would be interesting to determine whether such improvements are also seen in dKO mice. If not, then the findings would corroborate our data arguing that utrophin A is key in mediating the beneficial adaptations of dystrophic muscle linked to the induction of the slower, more oxidative phenotype in post-natal muscles. It is important to also note that these inducible transgenic mouse experiments followed a timeline similar to our pharmacological study which, in our view, is more relevant for eventual clinical interventions with DMD patients.
In conclusion, it appears increasingly evident now that administration of small molecules or drugs capable of activating signaling pathways that promote expression of the slower, more oxidative myofiber program represents a therapeutically viable avenue for treating DMD as we suggested several years ago. AICAR has not been used very extensively in clinical settings and it may have negative side effects such as lipoatrophy and hepatic hypertrophy (49, 73) . In this context, one can even envisage therefore, repurposing drugs currently employed in the clinic for treating other non-neuromuscular disorders that also activate AMPK. An attractive candidate in this case may be metformin because this drug activates AMPK and is used extensively in the clinic for treating type 2 diabetes. As shown in the work presented here, increased expression of utrophin A, which accompanies induction of the slow, oxidative phenotype, is central to this beneficial muscle plasticity and adaptive phenotype and is thus necessary to mitigate the progression of the dystrophic process following appropriate pharmacological therapy.
Materials and Methods
Animal care, breeding and genotyping pronase was added to the tissue lysis buffer from a 40× stock (20 mg/ml Pronase in 10 m Tris-HCl, pH 7.5, 10 m NaCl). Genotyping was performed on isolated DNA using two polymerase chain reactions ran for each animal. Both reactions used 12.5 µl 2X KAPA 2G Fast HS Genotyping Mix (KM5606; KAPA Biosystems, Wilmington, USA), 1.25 µl forward primer (10 µ), 1.25 µl reverse primer (10 µ), 0.5 µl MgCl 2 (25 m), 8.5 µl H 2 O and 100 ng of the DNA extracted from the animals tissue, for a total volume of 25 µl. One reaction used the mutant forward primer (CGC TTC CTC GTG CTT TAC GGT AT), while the other used the wild-type forward primer (TGT CAT TCT CTG AGG CCT TTC). Both reactions used the common reverse primer (AAG ATT TGC AGA CCG GAA GA). The reactions were run in a T100 Thermal Cycler (Bio-Rad, Mississauga, Canada) and PCR products were analyzed in agarose gel containing ethidium bromide.
Activation of AMPK with AICAR treatment
The AICAR treatment of mdx and dKO mice was performed according to the protocol and dosage described in our recent work (31) , which has been shown to induce the slower, more oxidative myogenic program in murine models (31, 41, 48, 50, 74) . AICAR (TRC, Toronto, Canada) was dissolved daily in sterile saline at 50 mg/ml prior to treatments. Three-to four-week-old dKO and mdx mice were treated every day with vehicle or AICAR (500 mg/kg/day) by subcutaneous interscapular injections for 28 days.
Western blotting
Muscle samples were dissected immediately after the mice were euthanized. Muscles were snap frozen in liquid nitrogen and stored at −80°C until use. Tissues were first ground with a mortar and pestle on dry ice and 300-500 µl of lysis buffer [7  urea, 2  thiourea, 4  3-[(3-cholamidopropyl) dimethylammonio]-1-propanesulfonate, 100 m dithiothreitol, 125 m Tris-HCl, pH 6.8, complete miniprotease inhibitor (Roche, Laval, Canada), Phos-STOP phosphatase inhibitor (Roche, Laval, Canada)] was added. Constant agitation was maintained on a vortex for 30 min at room temperature. The samples were then centrifuged at 16,000g for 15 min and the supernatant stored at −20°C. Protein concentration in the supernatants was quantified using a CB-X assay (G-Biosciences, St. Louis, USA), with bovine serum albumin as the standard.
Muscle proteins were resolved using sodium dodecyl sulfatepolyacrylamide gel electrophoresis (5-10% polyacrylamide) and were electroblotted onto nitrocellulose membranes (Bio-Rad, Mississauga, Canada). The membranes were stained with Ponceau S solution (0.1% Ponceau S in 1% acetic acid) to ensure equal loading and efficient transfer of the protein samples. Membranes were washed with tris-Buffered saline and tween 20 (TBST) (137 m NaCl, 2.7 m KCl, 19 m Tris base, 0.1% Tween 20) and blocked with blocking solution (5% milk in TBST) for 1 h at room temperature. The appropriate dilution of primary antibody was applied to the membrane in blocking solution or 5% BSA in TBST (for AMPK antibodies) overnight at 4°C. The antibodies used were: AMPKα (Cell Signaling 2532; Whitby, Canada), Phospho-AMPKα (Cell signaling 2531; Whitby, Canada), utrophin A (Novocastra; Concord, Canada), PGC-1α (Abcam ab72230; Toronto, Canada), RIP140 (Abcam ab342; Toronto, Canada), SIRT1 (Millipore 09-844; Billerica, USA), glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (Advanced ImmunoChemical 2-RGM2 6C5; Long Beach, USA), Troponin (Santa Cruz sc8119; Dallas, USA), OXPHOS complexes (Mitosciences MS604; Eugene, USA) and cytochrome c (a generous gift from Dr David A. Hood, Muscle Health Research Centre, York University, Toronto, Canada). After the incubation period, primary antibodies were washed 3 × 5 min in TBST. The appropriate dilution of secondary antibody coupled to horseradish peroxidase was applied to the membrane in blocking solution for 1 h at room temperature. The membrane was washed 3 × 5 min in TBST and visualized with enhanced chemiluminescence (Western Lighting ECL; PerkinElmer, Woodbridge, Canada). The blot was developed in a darkroom and the films (CL-X Posure; Thermo Scientific, Rockford, USA) were scanned and analyzed using ImageJ (NIH).
Immunofluorescence and haematoxylin and eosin staining
Muscle samples were dissected, immediately embedded in Tissue-Tek OCT Compound (Sakura Finetek, Torrance, USA), frozen in melting isopentane pre-cooled with liquid nitrogen and then stored at −80°C until use. Ten microns sections were obtained and stained overnight at 4°C using the following primary antibodies: utrophin A (Novocastra NCL-DRP2; Concord, Canada), Laminin (Sigma-Aldrich, Oakville, Canada) and MHC I and MHC II A. Appropriate tetramethylrhodamin-conjugated anti-rabbit antibodies and/or fluorescein (FITC)-conjugated anti-mouse antibodies were used for secondary detection. For immunoglobulin (IgM) staining, a FITC-conjugated IgM anti-mouse secondary antibody (Sigma-Aldrich, Oakville, Canada) was used. Slides containing tissue sections were mounted using Vectashield mounting medium (Vector Laboratories, Burlington, Canada) and covered. They were visualized at 5-20× with a fluorescent microscope, and high resolution images were acquired and quantified using ImageJ and Northern Eclipse Software (NES; Empix Imaging, Mississauga, Canada).
Muscle cross sections (10 µ) were also stained with hematoxylin and eosin, dehydrated through ascending, graded ethanol washes, cleared with toluene, and then mounted with Permount (Fisher Scientific, Ottawa, Canada). They were visualized at 10× magnification using a light microscope and the ratio of myofibers with centralized nuclei to the total number of fibers in the muscle section was counted from the acquired high resolution images.
Ex-vivo eccentric contractions
After 4 weeks of AICAR treatment, the animals were euthanized and their EDL muscles dissected. One tendon of the EDL muscle was attached to a Cambridge ergometer (model 6350*358; Aurora Scientific, Aurora, Canada), while the other was attached to a metal pin. The muscle was continuously bathed in saline-containing 0.1% trypan blue (Sigma-Aldrich, Oakville, Canada), with a flow rate of 15 ml/min at room temperature. The muscle length was adjusted to ensure maximal force output, and the force output at that length was monitored for consistency for 30 min. The muscle was subjected to five maximal twitch contractions (400 ms train duration, 10 V, 0.3 ms square pulse, 200 Hz) at 100 s intervals to determine muscle contractile kinetics, followed by 12 EC at 120 s intervals (700 ms train duration, 10 V, 0.3 ms square pulse, 200 Hz) (model S88; Grass Technologies, West Warwick, USA). During the last 200 ms of the EC, 10% lengthening at a velocity of 0.5 length/s was applied. Throughout the experiment, force was recorded using a Keithley data acquisition board (model KPCI-3104, Cleveland, USA) at a sample rate of 5 KHz. After, the EC, muscles were embedded in Tissue-Tek OCT Compound (Sakura Finetek, Torrance, USA), frozen in melting isopentane pre-cooled by liquid nitrogen, and then stored at −80C until use. Cross sections (10 µm) were observed at 10× magnification for intracellular red fluorescence, which indicates trypan blue infiltration within muscle fibers. Peripheral fibers in the muscle sections were omitted from the analysis due to possible damage during the dissection and/or the experimental manipulation.
Forelimb grip strength
The same animals that were used for the ex-vivo EC were first used for the grip test. Starting at 3 days before the AICAR treatment was completed, the mice were handled two to three times daily to get them used to being handled. After the final AICAR injection, the mice were moved to the testing room 1 h before the test began and left there to habituate. The mice were allowed to acclimatize near the triangular grid of the Chatillion DFE II (Columbus Instruments, Columbus, USA) grip strength meter for 60 s. The mouse was then moved closer to the meter until it had a firm grip on the bar. The mouse was pulled horizontally away from the bar at a speed of ∼2.5 cm/s, until it released the bar. The value of the maximal peak force was recorded. This was repeated five times for each animal, with a waiting time of 10-15 s between each measurement.
Statistical analysis
The data were analyzed for statistical significance using paired and unpaired Student's t-tests and analysis of variance (ANOVA) followed by post-hoc tests as appropriate (StatPlus, Vancouver, Canada). In the graphs depicted as fold differences, statistical analysis was first using the raw data prior to conversion to the fold difference values. Significance was accepted at P < 0.05.
